AcelRx Pharmaceuticals Inc (ACRX)
0.70
-0.02
(-2.76%)
USD |
NASDAQ |
Mar 24, 16:00
0.6895
-0.01
(-1.50%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 5.136M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -88.91% |
| Valuation | |
| PE Ratio | 0.1101 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.219 |
| Price to Book Value | 0.1887 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2863 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.58% |
News
Headline
Wire
Time (ET)
PR Newswire
03/21 16:05
Yahoo
03/01 08:30
PR Newswire
12/27 08:30
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/16/2023* | 08:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/16/2023* | -- | Results | Q1 2023 | -- | -1.39 | -- | |
| 11/14/2022 | -- | Results | Q3 2022 | -0.94 | -1.20 | 21.67% | |
| 11/14/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/11/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/11/2022 | -- | Results | Q2 2022 | -1.15 | -1.20 | 3.90% | |
| 05/16/2022 | 08:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 05/16/2022 | -- | Results | Q1 2022 | -1.20 | -1.20 | 0.00% |
*Estimated Date/Time
Earnings
Profile
Edit
| AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States. |
| URL | https://www.acelrx.com |
| Investor Relations URL | http://ir.acelrx.com/phoenix.zhtml?c=241441&p=irol-irhome |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 16, 2023 (est.) |
| Last Earnings Release | Nov. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
| Revenue (TTM) | 1.521M |
| Total Expenses (TTM) | 34.00M |
| Net Income (TTM) | 47.32M |
| Total Assets (Quarterly) | 48.31M |
| Total Liabilities (Quarterly) | 20.77M |
| Shareholders Equity (Quarterly) | 27.54M |
| Cash from Operations (TTM) | -30.92M |
| Cash from Investing (TTM) | 29.35M |
| Cash from Financing (TTM) | 6.032M |
Ratings
Profile
Edit
| AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States. |
| URL | https://www.acelrx.com |
| Investor Relations URL | http://ir.acelrx.com/phoenix.zhtml?c=241441&p=irol-irhome |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 16, 2023 (est.) |
| Last Earnings Release | Nov. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ACRX Tweets |